A phase 1b/2 study combining MM-151 + nal-IRI + 5-FU + leucovorin in RAS-wildtype metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS3633-TPS3633
10.1200/jco.2016.34.15_suppl.tps3633